Biological response modifiers

realizing their potential in cancer therapeutics

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The therapeutic activity of biological response modifiers has only recently been observed in cancer patients although some have in fact been in use for the past 35 years. Several cloned immunoregulatory agents such as the interleukins and bacterial adjuvants such as BCG have apparently shown disappointing therapeutic activity in the clinic but James Talmadge explains that the design of Phase I trials may yield insufficient information to assess accurately the immunomodulatory and clinical effects of potentially useful biological response modifiers.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalTrends in Pharmacological Sciences
Volume7
Issue numberC
DOIs
StatePublished - Jan 1 1986

Fingerprint

Immunologic Factors
Interleukins
Mycobacterium bovis
Ambulatory Care Facilities
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Biological response modifiers : realizing their potential in cancer therapeutics. / Talmadge, James E.

In: Trends in Pharmacological Sciences, Vol. 7, No. C, 01.01.1986, p. 277-281.

Research output: Contribution to journalArticle

@article{48498bc366694e3483ab18a85c5780f7,
title = "Biological response modifiers: realizing their potential in cancer therapeutics",
abstract = "The therapeutic activity of biological response modifiers has only recently been observed in cancer patients although some have in fact been in use for the past 35 years. Several cloned immunoregulatory agents such as the interleukins and bacterial adjuvants such as BCG have apparently shown disappointing therapeutic activity in the clinic but James Talmadge explains that the design of Phase I trials may yield insufficient information to assess accurately the immunomodulatory and clinical effects of potentially useful biological response modifiers.",
author = "Talmadge, {James E}",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/0165-6147(86)90352-4",
language = "English (US)",
volume = "7",
pages = "277--281",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "C",

}

TY - JOUR

T1 - Biological response modifiers

T2 - realizing their potential in cancer therapeutics

AU - Talmadge, James E

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The therapeutic activity of biological response modifiers has only recently been observed in cancer patients although some have in fact been in use for the past 35 years. Several cloned immunoregulatory agents such as the interleukins and bacterial adjuvants such as BCG have apparently shown disappointing therapeutic activity in the clinic but James Talmadge explains that the design of Phase I trials may yield insufficient information to assess accurately the immunomodulatory and clinical effects of potentially useful biological response modifiers.

AB - The therapeutic activity of biological response modifiers has only recently been observed in cancer patients although some have in fact been in use for the past 35 years. Several cloned immunoregulatory agents such as the interleukins and bacterial adjuvants such as BCG have apparently shown disappointing therapeutic activity in the clinic but James Talmadge explains that the design of Phase I trials may yield insufficient information to assess accurately the immunomodulatory and clinical effects of potentially useful biological response modifiers.

UR - http://www.scopus.com/inward/record.url?scp=0022649427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022649427&partnerID=8YFLogxK

U2 - 10.1016/0165-6147(86)90352-4

DO - 10.1016/0165-6147(86)90352-4

M3 - Article

VL - 7

SP - 277

EP - 281

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - C

ER -